Get started
Author

J P Guastalla

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
2019 · Xavier Pivot, Gilles Romieu, et al. · The Lancet · 130
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates
2007 · C.B. Confavreux, A. Fontana, et al. · Bone · 122
Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).
2010 · T Bachelot, C Bourgier, et al. · Cancer Research · 59
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
1999 · M A Mahé, P Fumoleau, et al. · PubMed · 58
Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule
2007 · G.J. Peters, M. Clavel, et al. · Journal of Chemotherapy · 45
Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer
2012 · X Pivot, G Romieu, et al. · Cancer Research · 37
Phase I study of gemcitabine using a once every 2 weeks schedule
1997 · JB Vermorken, JP Guastalla, et al. · British Journal of Cancer · 25
Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer
2012 · X. Pivot, G. Romieu, et al. · Annals of Oncology · 16
PDF
Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
2007 · on behalf of the French Adjuvant Study Group, P Kerbrat, et al. · British Journal of Cancer · 13
PDF
Impact of screening on clinicopathological features and treatment for invasive breast cancer: Results of two national surveys
2015 · B. Cutuli, F. Dalenc, et al. · Cancer/Radiothérapie · 12
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
1997 · E Pujade-Lauraine, J P Guastalla, et al. · PubMed · 11
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy
1994 · Y. Merrouche, G. Catimel, et al. · Annals of Oncology · 9
Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.
1996 · C Lhommé, P Kerbrat, et al. · PubMed · 8
Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer
2010 · M Martin, J Mackey, et al. · Cancer Research · 3
Standards, Options et Recommandations pour la prise en charge de patientes atteintes de cancer invasif du col utérin (stade non métastatique) (version abrégée)
2002 · Resbeut M., Fondrinier E., et al. · Gynécologie Obstétrique & Fertilité · 2
Standards, options et recommandations pour la prise en charge initiale des patientes atteintes de tumeurs épithéliales malignes de l'ovaire (version abrégée)
2001 · Kerbrat P., Lhommé C., et al. · Gynécologie Obstétrique & Fertilité · 2
5193 Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial
2009 · I. Ray-Coquard, J. Provençal, et al. · European Journal of Cancer Supplements · 1
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
2003 · M.S Aapro, F.H van Wijk, et al. · European Journal of Cancer · 1
[Chemotherapy of cancer of the breast in the metastatic phase].
1989 · M Clavel, P Biron, et al. · PubMed · 1
Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study
2012 · Florian Lordick, Pauline Wimberger, et al.
Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial
2012 · Florian Lordick, J. Sehouli, et al.
Tolérance comparée des différents traitements médicaux adjuvants chez la femme jeune
2010 · J P Guastalla, Fra Société française de sénologie et de pathologie mammaire · HAL
Joint Disorders Frequency and Structural Changes during Anastrozole Adjuvant Treatment in Early Breast Cancer: A Prospective Trial (D5392L00013).
2009 · T. Delozier, A. Daban, et al. · Cancer Research
00043: the New French Trophoblastic Disease Reference Center: 5-year Results
2005 · E. Golfier, D. Raudrant, et al. · International Journal of Gynecological Cancer
[Phase I pharmacokinetics of flavone-acetic acid].
1989 · B Tranchand, F Nasri, et al. · PubMed
Works count: 25
Citation count: 555
H-index: 11
I10-index: 11
Year
Topic
Type